|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/28 | |||
| A61P 35/00 | |||
| A61P 37/00 |
| (11) | Number of the document | 3154581 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15747597.1 |
| Date of filing the European patent application | 2015-06-15 | |
| (97) | Date of publication of the European application | 2017-04-19 |
| (45) | Date of publication and mention of the grant of the patent | 2019-02-20 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/035832 |
| Date | 2015-06-15 |
| (87) | Number | WO 2015/195556 |
| Date | 2015-12-23 |
| (30) | Number | Date | Country code |
| 201462012864 P | 2014-06-16 | US |
| (72) |
CHILDS, Richard, W., US
BERG, Maria, US
CALDERON, Luis, Espinoza, US
SASSER, Kate, US
ATTAR, Ricardo, US
|
| (73) |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services,
National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard Suite 325 MSC 7660, Bethesda, MD 20852-7660,
US
Janssen Biotech, Inc., 1400 Mckean Road, Spring House, PA 19477, US |
| (54) | BLOCKING CD38 USING ANTI-CD38 F(AB`)2 TO PROTECT NK CELLS |
| BLOCKING CD38 USING ANTI-CD38 F(AB`)2 TO PROTECT NK CELLS |